Breast cancer therapy based on melatonin

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 108-116

  Sanchez Barcelo, Emilio J ^a   Mediavilla, Maria D ^a   Alonso Gonzalez, Carolina ^a   Rueda, Noemi ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Antiestrogen; Aromatase; Breast cancer; MCF 7; Melatonin; SEEM; SERM; Xenoestrogens

Indexed keywords

BENZOFURAN DERIVATIVE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MELATONIN; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; S 23219 1; S 23478 1; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLUE LIGHT; BREAST CANCER; BREAST TUMOR; CANCER RISK; CARCINOGENICITY; CIRCADIAN RHYTHM; DRUG EFFECT; DRUG MECHANISM; HORMONE ACTION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; ILLUMINATION; LIGHT DARK CYCLE; NONHUMAN; PATENT; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RISK FACTOR;

EID: 84860474982     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604581     Document Type: Article

References (102)

1. Stockwell S. Classics in oncology. George Thomas Beatson, M.D. (1848-1933). CA Cancer J Clin 1983; 33:105-21.
2. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V. Endocrine therapy of breast cancer. Curr Med Chem 2011; 18:513-22.
3. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 2011; 12:496-503.
4. Barker S. Anti-estrogens in the treatment of breast cancer: Current status and future directions. Curr Opin Invest Drugs 2003; 4:652-7
5. Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 2004; 90:20-5.
6. Sengupta S, Jordan VC Selective estrogen modulators as an anticancer tool: Mechanisms of efficiency and resistance. Adv Exp Med Biol 2008; 630:206-19.
7. Reiter RJ. The pineal gland and its hormones in the control of reproduction in mammals. Endocr Rev 1980; 1: 109-31.
8. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 1978; 2: 814-6.
9. Cos S, Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21:133-70.
10. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17:4462-81.
11. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin-Receptors. Pharmacol Rev 2010; 62:343-80.
12. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin: A pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011; 93:350-84.
13. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 1981; 41: 4432-6.
14. Tamarkin L, Danforth D, Lichter A, DeMoss E, Cohen M, Chabner B, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982; 216:1003-5.
15. Blask DE, Hill SM. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm Suppl 1986; 21:433-49.
16. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48:6121-6.
17. Cos S, Sanchez-Barcelo EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett 1994; 85:105-9.
18. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 1999; 13:857-68.
19. Cos S, Fernández R, Güezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58:4383-90.
20. Sommers CL, Byers SW, Thompson E, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31:325-35.
21. Yagasaki R, Noguchi M, Minami M, Earashi M. Clinical significance of E-cadherin and vimentin co-expression in breast cancer. Int J Oncol 1996; 9:755-61.
22. Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010; 12:R107.
23. Molis TM, Spriggs LL, Jupiter Y, Hill SM. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 1995; 18:93-103.
24. Bizzarri M, Cucina A, Valente MG, Tagliaferri F, Borrelli V, Stipa F, et al. Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. J Surg Res 2003; 110:332-7.
25. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type b transforming growth factor: A bifunctional regulator of cell growth. Proc Natl Acad Sci USA 1985; 119-23.
26. Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65:415-20.
27. Cucina A, Proietti S, D'Anselmi F, Coluccia P, Dinicola S, Frati L, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46:172-80.
28. Girgert R, Hanf V, Emons G, Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 2009; 47:23-31.
29. Mediavilla MD, Güezmez A, Ramos S, Kothari L, Garijo F, Sánchez Barceló EJ. Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J Pineal Res 1997; 22:86-94.
30. Leon-Blanco M, Guerrero JM, Reiter RJ, Calvo JR, Pozo D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line in vivo and in vitro. J Pineal Res 2003; 35:204-11.
31. Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A, Sanchez-Barcelo EJ. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 2008; 268:272-7.
32. Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuño D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res 2002; 32:90-6.
33. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60:1407-26.
34. Darbre PD. Metalloestrogens: An emerging class of inorganic xenoestrogens with potential to add to the oestrogenic burden of the human breast. J Appl Toxicol 2006; 26:191-7.
35. Waalkes MP, Coogan TP, Barter RA. Toxicological principles of metal carcinogenesis with special emphasis on cadmium. Crit Rev Toxicol 1992; 22:175-201.
36. Martin MB, Reiter R, Pham T, Avellanet YR, Camara J, Lahm M, et al. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology 2003; 144: 2425-36.
37. Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, Clarke R, et al. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nature 2003; 9:1081-4.
38. International Agency for Research on Cancer (IARC). Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. In: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans Vol. 28. IARC Scientific Publications, Lyon, 1993; 119-37.
39. Martinez-Campa C, Alonso-Gonzalez C, Mediavilla MD, Cos S, Gonzalez A, Ramos S, et al. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res 2006; 40:291-6.
40. Alonso-González C, Gonzalez A, Mazarrasa O, Güezmes A, Sanchez-Mateos S, Martinez-Campa C, et al. Melatonin prevents the estrogenic effects of sub-chronic administration of cadmium on mice mammary glands and uterus. J Pineal Res 2007; 42:403-10.
41. Molis T, Walters M, Hill S. Melatonin modulation of estrogenreceptor expression in MCF-7 human breast-cancer cells. Int J Oncol 1993; 3:687-94.
42. Molis T, Spriggs LL, Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endo 1994; 8:1681-90.
43. Kiefer T, Ram PT, Yuan L, Hill SM. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002; 71:37-45.
44. Ram PT, Dai J, Tuan L, Dong C, Kiefer TL, Lai L, et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002; 179:141-50.
45. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002; 192:147-56.
46. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast cancer cell lines. Breast Cancer Res Treat 2009; 118:293-305.
47. Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 2003; 189:49-57.
48. Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, et al. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin. Breast Cancer Res Treat 2011; 127:91-8.
49. Lardone PJ, Guerrero JM, Fernandez-Santos JM, Rubio A, Martin-Lacave I, Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 2011; 51:454-62.
50. Dong C, Yuan L, Dai J, Lai L, Mao L, Xiang S, Rowan B, Hill SM. Melatonin inhibits mitogenic cross-talk between retinoic acidrelated orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells. Steroids 2010; 75:944-51.
51. Dai J, Ram PT, Yuan L, Spriggs LL, Hill SM. Transcriptional repression of ROR alpha activity in human breast cancer cells by melatonin. Mol Cell Endocrinol 2001; 176:111-20.
52. Li L, Sacks DB. Functional interactions between calmodulin and estrogen receptor-. Cell Signal 2007; 19:439-43.
53. Garcia Pedrero JM, Del Rio B, Martinez-Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol 2002; 16:947-60.
54. 2+/calmodulin-dependent kinase II activity by melatonin. Biochim Biophys Acta 1996; 1290:191-6.
55. Dai J, Inscho EW, Yuan L, Hill SM. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res 2002; 32:112-9.
56. Soto-Vega E, Meza I, Ramirez-Rodriguez G, Benitez-King G. Melatonin stimulates calmodulin phosphorylation by protein kinase C. J Pineal Res 2004; 37:98-106.
57. del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004; 279:38294-302.
58. Simpson E, Rubin G, Clyne C, Robertson K, O'Donnell L, Davis S, et al. Local estrogen biosynthesis in males and females. Endocr Relat Cancer 1999; 6:131-7.
59. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: A review. Biochim Biophys Acta 2004; 1654:123-43.
60. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005; 12:701-20.
61. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo E. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005; 38:136-42.
62. Martinez-Campa C, Gonzalez A, Mediavilla MD, Alonso-Gonzalez C, Sánchez-Barceló EJ, Cos S. Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat 2005; 94:249-54.
63. Cos S, Gonzalez A, Güezmes A, Mediavilla MD, Martinez-Campa C, Alonso-Gonzalez C, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006; 118:274-8.
64. Gonzalez A, Cos S, Martinez-Campa C, Alonso-Gonzalez C, Sanchez-Mateos, Mediavilla MD, et al. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 2008; 45:86-92.
65. Gonzalez A, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Mateos S, Hill SM, et al. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 2007; 17: 947-53.
66. Martinez-Campa C, Gonzalez A, Mediavilla MD, Alonso-Gonzalez C, Alvarez-Garcia V, Sánchez-Barceló EJ, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 2009; 101:1613-9.
67. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard, V, et al. Carcinogenicity of shiftwork, painting, and fire-fighting. Lancet Oncol 2007; 8:1065-6.
68. Reiter RJ, Tan DX, Korkmaz A, Erren TC; Piekarski C, Tamura H, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: A review. Crit Rev Oncog 2007; 13:303-28.
69. Erren TC, Reiter RJ. Defining chronodisruption. J Pineal Res 2009; 46:245-7.
70. Cos S, Mediavilla MD, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C, Sanchez-Barcelo EJ. Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats Cancer Lett 2006; 235:266-71.
71. Filipski E, Lévi F. Circadian disruption in experimental cancer processes. Integr Cancer Ther 2009; 8: 298-302.
72. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of breast cancer xenografts in nude rats. Cancer Res 2005; 65:11174-84.
73. Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD Light-mediated perturbations of circadian timing and cancer risk: A mechanistic analysis. Integr Cancer Ther 2009; 8:354-60.
74. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 1999; 80:1459-60.
75. Kliukiene J, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer 2001; 84:397-9.
76. Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ Health Perspect 2007; 115:1357-62.
77. Reiter RJ, Tan DX, Sanchez-Barcelo EJ, Mediavilla MD, Gitto E, Korkmaz A. Circadian mechanisms in the regulation of melatonin synthesis: Disruption with light at night and the pathophysiological consequences. J Exp Integ Med 2011; 1:13-22.
78. Hansen J. Light at night, shiftwork, and breast cancer risk. J Natl Cancer Inst 2001; 93:1513-5.
79. Hansen J. Risk of breast cancer after night-and shift work: Current evidence and ongoing studies in Denmark. Cancer Causes Control 2006;17:531-7.
80. Scherhammer ES, Laden F, Speizer FE, Willet WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses health study. J Natl Cancer Inst 2001; 93:1563-8.
81. Hansen MA, Garde HA, Hansen J. Diurnal urinary 6-sulfatoxymelatonin levels among healthy Danish nurses during work and leisure time. Chronobiol Int 2006; 23:1203-15.
82. Lockley SW, Brainard GC, Czeisler CA. High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab 2003; 88:4502-5.
83. West KE, Jablonski MR, Warfield B, Cecil KS, James M, Ayers MA, et al. Blue light from light-emitting diodes elicits a dose-dependent suppression of melatonin in humans. J Appl Physiol 2011; 110:619-26.
84. Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD. A novel human opsin in the inner retina. J Neurosci 2000; 20:600-5.
85. Sasseville A, Paquet N, Sévigny J, Hebert M. Blue blocker glasses impede the capacity of bright light to suppress melatonin production. J Pineal Res 2006; 41:73-8.
86. Mainster MA. Violet and blue light blocking intraocular lenses: Photoprotection versus photoreception. Br J Ophthalmol 2006; 90:784-92.
87. Clemens, J.A., Flaugh, M.E. Melatonin derivatives and combinations with antiestrogen compounds fro trating mammalian breast carcinoma. US5196435 (1993).
88. Sanchez-Barcelo EJ, Martinez-Campa CM, Mediavilla MD, Gonzalez A, Alonso-Gonzalez C, Cos S. Melatonin and melatoninergic drugs as therapeutic agents: Ramelteon and Agomelatine, the two most promising melatonin receptor agonists. Recent Pat Endocr Metab Immune Drug Discov 2007; 1:142-51.
89. Andrieux, J., Houssin, R., Yous, S., Guardiola, B., Lesieur, D. N-[2-(7-lower-alkoxynaphth-1-yl)ethyl]benzamides. US5318994 (1994).
90. Ohkawa, S., Uchikawa, O., Fukatsu, K, Miyamoto, M. Tricyclic compounds, their production and use. US6218429 (2001).
91. Mao L, Cheng Q, Guardiola-Lemaitre B, Schuster-Klein C, Dong C, Lai L, et al. In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 2010, 49:210-21.
92. Witt-Enderby, P.A., Davis, V.L. Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer. US20110028439 (2011).
93. Witt-Enderby, P.A., Davis, V.L. Lapinsky, D.J. Anti-cancer tamoxifen-melatonin hybrid. WO2011046596 (2011) & WO2011046596 (2011).
94. Yagi, H., Shimizu, M., Higashi, T., Kobayashi, Y. Fluorescent lamp. US20110037378 (2011).
95. Casper, R., Wardrop, J., Spilkin, J., Solo, P. Device for the prevention of melatonin suppression by light at night. US7520607 (2009).
96. Gruber, J.A. Retinal melatonin suppressor comprising a filtering layer. US7984989 (2011).
97. Brainard, G., Glickman, G. Photorreceptor system for melatonin regulation and phototherapy. US7678140 (2010).
98. Paul, M.L., Lowery, M.D., Laguette, S.W., Brandhauer, M.H. Intraocular lens having a visible light-selective-transmissiveregion. US8043371 (2011).
99. Manning, R.O. Anti-carcinogenic lights and lighting. US7034934 (2006).
100. Woog, K.M. Viewing screen color limiting device and method. US20060152525 (2006).
101. Kameyama, K., Suzuki, T., Ouchi, K. Apparatus, system and method for lighting control, and computer program product. US20070118026 (2007).
102. Tsuboi, M., Uchiumi, T., Kanako, T., Yamaka, A. US20100060195 (2010).